Abstract
T helper 17 (Th17) cells are a newly identified subset of T helper cells that play important roles in host defense against extracellular bacteria as well as in the pathogenesis of autoimmune disease. The functions of Th17 cells are mediated via the production of several cytokines including interleukin (IL)-17 and IL-22. Recent studies show that the frequency of IL-17+ cells is significantly elevated in a variety of chronic liver diseases including alcoholic liver disease, viral hepatitis and hepatocellular carcinoma. IL-17 receptor is expressed virtually on all types of liver cells, while IL-22 receptor expression is restricted to epithelial cells including hepatocytes in the liver. IL-17 seems to play an important role in inducing liver inflammation via stimulating multiple types of liver nonparenchymal cells to produce proinflammatory cytokines and chemokines, while IL-22 appears to be an important factor in promoting hepatocyte survival and proliferation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
O'Shea RS, Dasarathy S, McCullough AJ . Alcoholic liver disease. Hepatology 2010; 51: 307–328.
Torres DM, Harrison SA . Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682–1698.
Vuppalanchi R, Chalasani N . Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306–317.
Di Bisceglie AM . Hepatitis B and hepatocellular carcinoma. Hepatology 2009; 49: S56–S60.
Chang KM . Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2003; 7: 89–105.
Rehermann B . Intrahepatic T cells in hepatitis B: viral control versus liver cell injury. J Exp Med 2000; 191: 1263–1268.
Ichiki Y, Aoki CA, Bowlus CL, Shimoda S, Ishibashi H, Gershwin ME . T cell immunity in autoimmune hepatitis. Autoimmun Rev 2005; 4: 315–321.
Thiele GM, Freeman TL, Klassen LW . Immunologic mechanisms of alcoholic liver injury. Semin Liver Dis 2004; 24: 273–287.
Caldwell CC, Tschoep J, Lentsch AB . Lymphocyte function during hepatic ischemia/reperfusion injury. J Leukoc Biol 2007; 82: 457–464.
Alatrakchi N, Koziel M . Regulatory T cells and viral liver disease. J Viral Hepat 2009; 16: 223–229.
Dolganiuc A, Szabo G . T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. J Leukoc Biol 2008; 84: 614–622.
Dolganiuc A, Paek E, Kodys K, Thomas J, Szabo G . Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology 2008; 135: 2119–2127.
Longhi MS, Mitry RR, Samyn M, Scalori A, Hussain MJ, Quaglia A et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009; 50: 130–142.
Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328–2339.
Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234–243.
TrehanPati N, Geffers R, Sukriti, Hissar S, Riese P, Toepfer T et al. Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology 2009; 49: 781–790.
Zhang W, Sharma R, Ju ST, He XS, Tao Y, Tsuneyama K et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 2009; 49: 545–552.
Kido M, Watanabe N, Okazaki T, Akamatsu T, Tanaka J, Saga K et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008; 135: 1333–1343.
Stockinger B, Veldhoen M . Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19: 281–286.
Chen Z, O'Shea JJ . Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008; 41: 87–102.
Ouyang W, Kolls JK, Zheng Y . The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454–467.
Dong C . Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev 2008; 226: 80–86.
Zhou L, Littman DR . Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol 2009; 21: 146–152.
Chen Z, Laurence A, O'Shea JJ . Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007; 19: 400–408.
Ge D, You Z . Expression of interleukin-17RC protein in normal human tissues. Int Arch Med 2008; 1: 19.
Lafdil F, Wang H, Park O, Zhang W, Moritoki Y, Yin S et al. Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production. Gastroenterology 2009; 137: 2125-35 e1-2.
Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49: 646–657.
Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y . Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009; 157: 261–270.
Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007; 282: 27229–27238.
Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006; 177: 36–39.
Gaffen SL . An overview of IL-17 function and signaling. Cytokine 2008; 43: 402–407.
Tiegs G, Hentschel J, Wendel A . A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196–203.
Tiegs G . Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z Gastroenterol 2007; 45: 63–70.
Jaruga B, Hong F, Sun R, Radaeva S, Gao B . Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol 2003; 171: 3233–3244.
Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, Tian Z et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 2002; 110: 1503–1513.
Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA . Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647–659.
Nagata T, McKinley L, Peschon JJ, Alcorn JF, Aujla SJ, Kolls JK . Requirement of IL-17RA in Con A induced hepatitis and negative regulation of IL-17 production in mouse T cells. J Immunol 2008; 181: 7473–7479.
Bautista AP . Neutrophilic infiltration in alcoholic hepatitis. Alcohol 2002; 27: 17–21.
Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81–91.
Ge J, Wang K, Meng QH, Qi ZX, Meng FL, Fan YC . Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol 2009; in press.
Lan RY, Salunga TL, Tsuneyama K, Lian ZX, Yang GX, Hsu W et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009; 32: 43–51.
Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, O'Farrelly C et al. Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol 2008; 181: 4485–4494.
Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M . Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 2008; 226: 87–102.
Hsu W, Zhang W, Tsuneyama K, Moritoki Y, Ridgway WM, Ansari AA et al. Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(-/-) mice. Hepatology 2009; 49: 133–140.
Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50: 980–989.
Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L . Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010; 51: 154–164.
Murugaiyan G, Saha B . Protumor vs antitumor functions of IL-17. J Immunol 2009; 183: 4169–4175.
Radaeva S, Sun R, Pan HN, Hong F, Gao B . Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004; 39: 1332–1342.
Hamada S, Umemura M, Shiono T, Tanaka K, Yahagi A, Begum MD et al. IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver. J Immunol 2008; 181: 3456–3463.
Kobayashi E, Kobayashi M, Tsuneyama K, Fukami T, Nakajima M, Yokoi T . Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol Sci 2009; 111: 302–310.
Yasumi Y, Takikawa Y, Endo R, Suzuki K . Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol Res 2007; 37: 248–54.
Fabrega E, Lopez-Hoyos M, San Segundo D, Casafont F, Pons-Romero F . Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl 2009; 15: 629–633.
Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol 2007; 178: 5973–5981.
Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC . Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002; 277: 33676–33682.
Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS et al. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1019–G1028.
Wahl C, Wegenka UM, Leithauser F, Schirmbeck R, Reimann J . IL-22-dependent attenuation of T cell-dependent (ConA) hepatitis in herpes virus entry mediator deficiency. J Immunol 2009; 182: 4521–4528.
Pan H, Hong F, Radaeva S, Gao B . Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 2004; 1: 43–49.
Ren X, Hu B, Colletti LM . IL-22 is involved in liver regeneration after hepatectomy. Am J Physiol Gastrointest Liver Physiol 2010; 298: G74–G80.
Dambacher J, Beigel F, Zitzmann K, Heeg MH, Goke B, Diepolder HM et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 2008; 41: 209–216.
Acknowledgements
This work was supported by the intramural program of NIAAA, NIH.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lafdil, F., Miller, A., Ki, S. et al. Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol 7, 250–254 (2010). https://doi.org/10.1038/cmi.2010.5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2010.5
Keywords
This article is cited by
-
Multi-omics approaches for drug-response characterization in primary biliary cholangitis and autoimmune hepatitis variant syndrome
Journal of Translational Medicine (2024)
-
Increased circulating Th17 cell populations in patients with pancreatic ductal adenocarcinoma
Immunogenetics (2023)
-
In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome
Pharmaceutical Research (2022)
-
Stimulation of hepatocarcinogenesis by activated cholangiocytes via Il17a/f1 pathway in kras transgenic zebrafish model
Scientific Reports (2021)
-
Immunopathobiology and therapeutic targets related to cytokines in liver diseases
Cellular & Molecular Immunology (2021)